New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias

E. Carmeliet, H. A. Fozzard, M. Hiraoka, M. J. Janse, S. Ogawa, D. M. Roden, M. R. Rosen, Y. Rudy, P. J. Schwartz, P. S. Matteo, J. A. Camm, C. Antzelevitch, P. A. Boyden, W. A. Catterall, G. I. Fishman, A. L. George, S. Izumo, J. Jalife, C. T. January, A. G. KléberE. Marban, A. R. Marks, P. M. Spooner, A. L. Waldo, J. M. Weiss, D. P. Zipes

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cardiac arrhythmias complicate many diseases affecting the heart and the circulation, and incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashion facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies. Condensed Abstract: The evolution of scientific knowledge has made the effects of cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies.

Original languageEnglish (US)
Pages (from-to)345-360
Number of pages16
JournalCardiovascular Research
Volume52
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Cell Biology
Cardiac Arrhythmias
Drug Design
Therapeutics
Genetic Therapy
Cardiovascular Diseases
Pharmacology
Heart Diseases

Keywords

  • Antiarrhythmic agents
  • Gene therapy
  • Genes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Carmeliet, E., Fozzard, H. A., Hiraoka, M., Janse, M. J., Ogawa, S., Roden, D. M., ... Zipes, D. P. (2001). New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias. Cardiovascular Research, 52(3), 345-360. https://doi.org/10.1016/S0008-6363(01)00465-5

New approaches to antiarrhythmic therapy : Emerging therapeutic applications of the cell biology of cardiac arrhythmias. / Carmeliet, E.; Fozzard, H. A.; Hiraoka, M.; Janse, M. J.; Ogawa, S.; Roden, D. M.; Rosen, M. R.; Rudy, Y.; Schwartz, P. J.; Matteo, P. S.; Camm, J. A.; Antzelevitch, C.; Boyden, P. A.; Catterall, W. A.; Fishman, G. I.; George, A. L.; Izumo, S.; Jalife, J.; January, C. T.; Kléber, A. G.; Marban, E.; Marks, A. R.; Spooner, P. M.; Waldo, A. L.; Weiss, J. M.; Zipes, D. P.

In: Cardiovascular Research, Vol. 52, No. 3, 2001, p. 345-360.

Research output: Contribution to journalArticle

Carmeliet, E, Fozzard, HA, Hiraoka, M, Janse, MJ, Ogawa, S, Roden, DM, Rosen, MR, Rudy, Y, Schwartz, PJ, Matteo, PS, Camm, JA, Antzelevitch, C, Boyden, PA, Catterall, WA, Fishman, GI, George, AL, Izumo, S, Jalife, J, January, CT, Kléber, AG, Marban, E, Marks, AR, Spooner, PM, Waldo, AL, Weiss, JM & Zipes, DP 2001, 'New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias', Cardiovascular Research, vol. 52, no. 3, pp. 345-360. https://doi.org/10.1016/S0008-6363(01)00465-5
Carmeliet, E. ; Fozzard, H. A. ; Hiraoka, M. ; Janse, M. J. ; Ogawa, S. ; Roden, D. M. ; Rosen, M. R. ; Rudy, Y. ; Schwartz, P. J. ; Matteo, P. S. ; Camm, J. A. ; Antzelevitch, C. ; Boyden, P. A. ; Catterall, W. A. ; Fishman, G. I. ; George, A. L. ; Izumo, S. ; Jalife, J. ; January, C. T. ; Kléber, A. G. ; Marban, E. ; Marks, A. R. ; Spooner, P. M. ; Waldo, A. L. ; Weiss, J. M. ; Zipes, D. P. / New approaches to antiarrhythmic therapy : Emerging therapeutic applications of the cell biology of cardiac arrhythmias. In: Cardiovascular Research. 2001 ; Vol. 52, No. 3. pp. 345-360.
@article{f179cfff20054de59a8c5495127f76cf,
title = "New approaches to antiarrhythmic therapy: Emerging therapeutic applications of the cell biology of cardiac arrhythmias",
abstract = "Cardiac arrhythmias complicate many diseases affecting the heart and the circulation, and incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashion facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies. Condensed Abstract: The evolution of scientific knowledge has made the effects of cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies.",
keywords = "Antiarrhythmic agents, Gene therapy, Genes",
author = "E. Carmeliet and Fozzard, {H. A.} and M. Hiraoka and Janse, {M. J.} and S. Ogawa and Roden, {D. M.} and Rosen, {M. R.} and Y. Rudy and Schwartz, {P. J.} and Matteo, {P. S.} and Camm, {J. A.} and C. Antzelevitch and Boyden, {P. A.} and Catterall, {W. A.} and Fishman, {G. I.} and George, {A. L.} and S. Izumo and J. Jalife and January, {C. T.} and Kl{\'e}ber, {A. G.} and E. Marban and Marks, {A. R.} and Spooner, {P. M.} and Waldo, {A. L.} and Weiss, {J. M.} and Zipes, {D. P.}",
year = "2001",
doi = "10.1016/S0008-6363(01)00465-5",
language = "English (US)",
volume = "52",
pages = "345--360",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - New approaches to antiarrhythmic therapy

T2 - Emerging therapeutic applications of the cell biology of cardiac arrhythmias

AU - Carmeliet, E.

AU - Fozzard, H. A.

AU - Hiraoka, M.

AU - Janse, M. J.

AU - Ogawa, S.

AU - Roden, D. M.

AU - Rosen, M. R.

AU - Rudy, Y.

AU - Schwartz, P. J.

AU - Matteo, P. S.

AU - Camm, J. A.

AU - Antzelevitch, C.

AU - Boyden, P. A.

AU - Catterall, W. A.

AU - Fishman, G. I.

AU - George, A. L.

AU - Izumo, S.

AU - Jalife, J.

AU - January, C. T.

AU - Kléber, A. G.

AU - Marban, E.

AU - Marks, A. R.

AU - Spooner, P. M.

AU - Waldo, A. L.

AU - Weiss, J. M.

AU - Zipes, D. P.

PY - 2001

Y1 - 2001

N2 - Cardiac arrhythmias complicate many diseases affecting the heart and the circulation, and incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashion facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies. Condensed Abstract: The evolution of scientific knowledge has made the effects of cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies.

AB - Cardiac arrhythmias complicate many diseases affecting the heart and the circulation, and incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashion facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies. Condensed Abstract: The evolution of scientific knowledge has made the effects of cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies.

KW - Antiarrhythmic agents

KW - Gene therapy

KW - Genes

UR - http://www.scopus.com/inward/record.url?scp=0035217022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035217022&partnerID=8YFLogxK

U2 - 10.1016/S0008-6363(01)00465-5

DO - 10.1016/S0008-6363(01)00465-5

M3 - Article

C2 - 11738052

AN - SCOPUS:0035217022

VL - 52

SP - 345

EP - 360

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -